SPARK supports $12 million series B funding for Vivacta
SPARK Ventures has provided follow-on funding of £1 million to Vivacta, a vitro diagnostic company, as part of the company’s £5.7 million Series B financing round. This financing will be used to commercialise Vivacta’s first Point of Care (PoC) immunoassay system.
News